Curated News
By: NewsRamp Editorial Staff
September 10, 2025
Oncotelic Taps IBN for Strategic Communications Amid Cancer Drug Development
TLDR
- Oncotelic Therapeutics gains strategic advantage by partnering with IBN for corporate communications, enhancing visibility for its Phase 3 pancreatic cancer drug and AI-driven pipeline.
- Oncotelic Therapeutics employs its proprietary AI platform PDAOAI and 45% stake in GMP Bio to systematically advance multiple drug candidates through regulatory filings and clinical trials.
- Oncotelic Therapeutics is developing innovative RNA-based treatments for pediatric cancers and rare diseases, potentially improving survival and quality of life for underserved patient populations.
- Oncotelic's CEO Dr. Vuong Trieu, co-inventor of Abraxane, leads a company with 39 US patents and a joint venture capable of supporting 20 drug candidates.
Impact - Why it Matters
This development matters because Oncotelic's work addresses some of the most challenging cancers and rare pediatric diseases where treatment options are severely limited. The company's Phase 3 trial for pancreatic ductal adenocarcinoma targets one of the deadliest cancers with a five-year survival rate of just 10%. Their RNA-based immunotherapy approach represents a potentially groundbreaking advancement in cancer treatment. For patients and families facing these devastating diagnoses, Oncotelic's research could mean new hope and life-extending treatments. Additionally, the enhanced communications strategy through IBN increases transparency and investor awareness, which is crucial for securing funding to advance these potentially life-saving therapies through clinical trials and ultimately to patients in need.
Summary
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company, has selected IBN to spearhead its corporate communications as it advances innovative treatments for cancer and underserved diseases. Led by Chairman and CEO Dr. Vuong Trieu, co-inventor of Abraxane, the company is developing RNA-based immunotherapies and targeted treatments, with its lead candidate OT-101 currently in a Phase 3 trial for pancreatic ductal adenocarcinoma. Oncotelic's multi-asset pipeline focuses on difficult-to-treat conditions including pediatric cancers and aggressive solid tumors, supported by proprietary AI platform PDAOAI and a 45% stake in GMP Biotechnology Limited.
The company's strategic partnership with IBN, part of the Dynamic Brand Portfolio, will leverage extensive corporate communications solutions including wire distribution, article syndication to 5,000+ outlets, press release enhancement, and social media distribution via IBN to millions of followers. This enhanced visibility comes at a critical time as Oncotelic continues to build upon Dr. Trieu's impressive portfolio of over 150 patent applications and 39 issued U.S. patents, positioning the company for significant growth in oncology and rare disease therapeutics. The collaboration aims to maximize investor awareness and public recognition as the company progresses its clinical programs and expands its innovative treatment offerings.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic Taps IBN for Strategic Communications Amid Cancer Drug Development
